Neoleukin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
March 02, 2021 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, March 02, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days
February 05, 2021 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Receives Clinical Hold Letter from U.S. FDA Related to CMC Assay Development for NL-201
January 08, 2021 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics to Present at J.P. Morgan Healthcare Conference
January 07, 2021 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Announces Submission of Investigational New Drug Application for NL-201 De Novo Protein Immunotherapy Candidate for Cancer
December 10, 2020 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Announces Participation in Piper Sandler 32nd Annual Virtual Healthcare Conference
November 23, 2020 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference
November 11, 2020 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Presents Preclinical Combination Data for NL-201 at Society for Immunotherapy of Cancer’s 35th Anniversary Annual Meeting (SITC 2020)
November 10, 2020 08:00 ET
|
Neoleukin Therapeutics, Inc.
- NL-201 enhances activity of checkpoint inhibitors and tumor-targeting antibodies and increases immune cell stimulation - SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics,...
Neoleukin Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Update
November 09, 2020 08:00 ET
|
Neoleukin Therapeutics, Inc.
-NL-201 IND submission anticipated by year end 2020- -Clinical Trial Notification application submitted in Australia- -Ended 3rd quarter with $201.2 million in cash and cash equivalents- ...
Neoleukin Therapeutics Announces Publication in Science of De Novo Protein Decoys that Block COVID-19 Infection In Vitro and Protect Animals In Vivo
November 05, 2020 14:00 ET
|
Neoleukin Therapeutics, Inc.
- Intranasal administration of NL-CVX1 protects hamsters from lethal SARS-CoV-2 infection – - Designed to resist viral mutational escape by mimicking the natural target of the spike protein - ...